Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 27, Issue 48, Pages 8357-8369Publisher
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v27.i48.8357
Keywords
Stomach neoplasms; Chemotherapy; Prognosis; Validation; Gastric cancer
Categories
Ask authors/readers for more resources
By analyzing clinical data of MRGC patients, six prognostic factors were identified. A simple and effective prognostic model was developed based on these factors, which can help predict patients' survival rates.
BACKGROUNDNew prognostic factors have been reported in patients with metastatic or recurrent gastric cancer (MRGC), necessitating modifications to the previous prognostic model.AIMTo develop a new model, MRGC patients who received fluoropyrimidines/platinum doublet chemotherapy between 2008 and 2015 were analyzed.METHODSA total of 1883 patients was divided into a training set (n = 937) and an independent validation set (n = 946).RESULTSMultivariate analysis showed that the following six factors were associated with poor overall survival (OS) in the training set: Eastern Cooperative Oncology Group performance score & GE; 2 and bone metastasis (2 points each), peritoneal metastasis, high alkaline phosphatase level, low albumin level, and high neutrophil-lymphocyte ratio (1 point each). A prognostic model was developed by stratifying patients into good (0-1 point), moderate (2-3 points), and poor (& GE; 4 points) risk groups. In the validation set, the median OS of the three risk groups was 15.8, 10.1, and 5.7 mo, respectively, and those differences were significant (P < 0.001).CONCLUSIONWe identified six factors readily measured in clinical practice that are predictive of poor prognosis in patients with MRGC. The new model is simpler than the old and more easily predicts OS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available